Clinical & Scientific

Shane Kovacs's exit from Olema Oncology introduces leadership questions as the biotech firm nears a pivotal data readout for its lead breast cancer drug.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

After Amgen steps back, Kyowa Kirin takes full control of its promising atopic dermatitis drug, rocatinlimab, betting on its unique science.

Following the departure of its R&D head, Immunocore streamlines leadership, betting on internal experts to drive its next wave of innovative therapies.

A new center in China is using a novel drug and special policies to offer hope against NUT carcinoma, a rare and deadly cancer affecting the young.

A new study in Nature Medicine shows a fasting-mimicking diet led to high remission rates in Crohn's patients, heralding a new era for 'Food as Medicine'.

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

A new partnership aims to accelerate a pipeline of innovative multi-functional fusion proteins, potentially reshaping treatment for cancer and autoimmune disease.

London's Ellipses Pharma in-licenses a novel B7H3 antibody-drug conjugate from Innolake, aiming to outmaneuver competitors with a unique payload.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

With a new CEO and promising data, Emmecell aims to replace corneal transplants with its magnetic cell delivery platform. But can it win in a competitive market?

Vaximm appoints Sébastien Wieckowski as CSO, leveraging his data science expertise to advance its oral cancer vaccine platform at a pivotal clinical stage.

Backed by Canada's life sciences engine adMare, new biotech firm Ocythera is advancing a unique non-retinoid therapy for debilitating bone disorders.

With its lead drug in human trials, ViroMissile hires a seasoned CBO to navigate the competitive oncolytic virus market and secure its future.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

Juvena Therapeutics lands a $33.5M Series B and a major pharma deal to advance its AI-discovered regenerative drugs for neuromuscular diseases.

With a new name and a laser focus on its lead hemophilia A drug, Metagenomi Therapeutics signals a major shift from platform tech to clinical powerhouse.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.